However, there was an improvement in overall survival (OS) with the combination versus gemcitabine alone, reaching nominal statistical significance. The safety profile observed was consistent with prior reported studies of nab-paclitaxel. Full findings will be presented at an upcoming medical meeting, stated Celgene, the manufacturer of nab-paclitaxel, in a press release. Read more . . .